Gilead director granted RSUs and stock options
Gilead Sciences director Javier Rodriguez received new equity awards as part of his compensation.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Gilead Sciences director Javier Rodriguez received new equity awards as part of his compensation. He was granted 1,146 restricted stock units, each representing one share of common stock, which vested immediately on April 30, 2026, raising his direct common stock holdings to 13,364 shares.
Rodriguez was also granted a non-qualified stock option for 4,884 shares of common stock at an exercise price of $130.84 per share. All of these option shares vested immediately on April 30, 2026 and are scheduled to remain exercisable until April 30, 2036.
Insider Trade Summary
Grant/Award: 6,030 shares
Grant/Award
2 txns
Insider
Rodriguez Javier
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Non-qualified Stock Option (Right to Buy) | 4,884 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 1,146 | $0.00 | $0.00 |
Holdings After Transaction:
Non-qualified Stock Option (Right to Buy) — 4,884 contracts (Direct);
Common Stock — 13,364 shares (Direct)
Footnotes (2)
- F1. Represents 1,146 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of April 30, 2026.
- F2. 100% of the shares subject to the stock option vested immediately upon the grant date of April 30, 2026.
Key Figures
Restricted stock units granted: 1,146 RSUs
Common shares after grant: 13,364 shares
Stock options granted: 4,884 options
+2 more
5 metrics
Restricted stock units granted
1,146 RSUs
Granted and vested immediately on April 30, 2026
Common shares after grant
13,364 shares
Direct common stock holdings following RSU grant
Stock options granted
4,884 options
Non-qualified stock option, fully vested on April 30, 2026
Option exercise price
$130.84 per share
Conversion or exercise price for 4,884-option grant
Option expiration date
April 30, 2036
Expiration for non-qualified stock option grant
Key Terms
restricted stock units, RSUs, Equity Incentive Plan, Non-qualified Stock Option, +1 more
5 terms
restricted stock units financial
"Represents 1,146 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
RSUs financial
"Represents 1,146 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan."
RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.
Equity Incentive Plan financial
"granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan."
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
Non-qualified Stock Option financial
"Non-qualified Stock Option (Right to Buy)"
A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.
vested immediately financial
"The RSUs vested immediately upon the grant date of April 30, 2026."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What equity awards did Gilead Sciences (GILD) director Javier Rodriguez receive?
Javier Rodriguez received 1,146 restricted stock units and a non-qualified stock option for 4,884 shares. Each RSU equals one Gilead common share, and the option allows him to buy additional shares at a fixed $130.84 exercise price.
When did Javier Rodriguez’s new Gilead (GILD) RSUs and options vest?
Both the 1,146 restricted stock units and all 4,884 stock option shares vested immediately on April 30, 2026. Immediate vesting means Rodriguez gained the full rights under these awards as of that grant date, subject to plan and agreement terms.
What is the exercise price and term of Javier Rodriguez’s Gilead stock options?
The non-qualified stock option covers 4,884 Gilead shares at a $130.84 exercise price. All shares vested immediately and the option is scheduled to remain exercisable until April 30, 2036, providing a long-dated right to purchase stock at that price.
Are Javier Rodriguez’s Gilead (GILD) Form 4 transactions open-market buys or sales?
The filing shows compensation-related acquisitions, not open-market trades. Rodriguez received restricted stock units and a stock option grant from Gilead, both at a grant price of $0.00 per share, rather than purchasing or selling shares in the open market.
AI-generated analysis. How Rhea-AI works. Not financial advice.
